Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

Long-term oral β-blocker therapy, including bisoprolol, metoprolol, and carvedilol, reduces the composite endpoint of all-cause death, new myocardial infarction, or heart failure by 25% in ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.

Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...

Ryan Haumschild, PharmD, MS, MBA: Dr Anderson, I’d like to start with you. We’ve talked about guideline recommendations. Can you briefly discuss some of the real-world differences in the treatment ...

Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.

A medication that is currently used for chronic kidney disease in patients with type 2 diabetes has been found to reduce the risk of worsening heart failure and cardiovascular death in certain people ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

Elevated baseline LDH levels predict worse clinical outcomes in heart failure with reduced ejection fraction and modestly ...